Compare BTBT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BTBT | ENGN |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 647.1M |
| IPO Year | 2017 | N/A |
| Metric | BTBT | ENGN |
|---|---|---|
| Price | $1.57 | $7.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.00 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 17.8M | 255.6K |
| Earning Date | 05-14-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,560,320.00 | N/A |
| Revenue This Year | $38.96 | N/A |
| Revenue Next Year | $89.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.25 | $2.66 |
| 52 Week High | $4.55 | $12.25 |
| Indicator | BTBT | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 42.11 |
| Support Level | $1.53 | $6.15 |
| Resistance Level | $2.43 | $7.33 |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 59.09 | 13.86 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.